Exercise rehabilitation trial in Huntington'’s disease

ISRCTN ISRCTN11392629
DOI https://doi.org/10.1186/ISRCTN11392629
Secondary identifying numbers 15832
Submission date
24/01/2014
Registration date
24/01/2014
Last edited
19/07/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Huntington's disease (HD) is an inherited neurological disease, which over time results in progressive problems with movement, thinking and behaviour, and ultimately difficulties in undertaking the usual activities of daily living. It is known that keeping physically active is important for any person who has a chronic health condition. Additionally, there is a growing interest in the potential that aerobic exercise may have for brain health, particularly for people with degenerative diseases such as HD. Engaging in regular exercise, however, can be difficult for people with HD given the complex and varied problems that they are faced with on a daily basis. This study aims to evaluate the feasibility and benefit of a supported, structured exercise intervention in people with early to mid-stage HD.

Who can participate?
Men and women aged 18 and over diagnosed with HD.

What does the study involve?
People with HD who enrol in the study will be asked to attend two research assessments (focussing on physical fitness, movement, thinking and walking abilities) over a three-month period at their local HD clinics. After the first assessment, they will be randomly allocated to either the exercise intervention group or the control group. In the intervention group, exercise trainers will work with each participant on an individualised exercise programme, either in their home or at a community gym. The intervention will take place three times per week for 12 weeks, and trainers will supervise the participant in just over half of the sessions. The remainder of the sessions will be conducted by the participant independently, or with the support of a carer or family member.

What are the possible benefits and risks of participating?
There may, or may not be, direct benefits to anyone taking part in this study. The study aims to find out whether or not the exercise intervention is safe, feasible and beneficial to people with HD. By taking part, participants will be helping us to answer this question, which may be of benefit to people with HD in the future. The assessments and intervention are unlikely to cause any undue stress. Care and comfort of participants will be ensured at all times. The proposed exercise training is of moderate intensity and has been developed in line with established protocols, and therefore poses minimal risk.

Where is the study run from?
Leiden (Netherlands), Munster (Germany), Cardiff (Wales), Birmingham (England), Oxford (England)

When is the study starting and how long is it expected to run for?
February 2014 to August 2014

Who is funding the study?
Jacques and Gloria Gossweiller Foundation (Switzerland)

Who is the main contact?
Ms Katy DeBono
debonok1@cardiff.ac.uk

Contact information

Ms Katy DeBono
Scientific

Department of Physiotherapy
Heath Park
Cardiff
CF14 4XN
United Kingdom

Email debonok1@cardiff.ac.uk

Study information

Study designRandomised interventional; Design type: Process of Care
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomised exercise rehabilitation trial in Huntington's disease
Study acronymExeRT-HD
Study objectivesThis randomised study aims to evaluate the feasibility (in terms of adherence, process and safety) and benefit of a supported, structured aerobic exercise intervention in people with early to mid-stage HD.
Ethics approval(s)South East Wales Research Ethics Committee, 06/11/2014, ref.:13/WA/0315
Health condition(s) or problem(s) studiedTopic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Huntington’s Disease; Disease: Huntington's disease
InterventionPeople with HD who enrol in the study will be asked to attend two research assessments (focussing on physical fitness, movement, thinking and walking abilities) over a three-month period at their local HD clinics or university research facilities. After the first assessment, they will be randomly allocated to either the an aerobic exercise programme group or the control group. If they are assigned to the intervention, professional trainers will work with each participant on an individualised exercise programme, either in their home or at a community gym. The intervention will take place three times per week for 12 weeks, and trainers will supervise the participant in just over half of the sessions. The remainder of the sessions will be conducted by the participant independently, or with support of a carer or family member.

Participants who are assigned to the control group will be instructed to continue as normal for the 13 weeks between assessments, and will be instructed to not begin any new exercise or physical activity routines. Following completion of the second assessment, the participants in the control group will be offered gym membership for 12 weeks, so long as the results from the intervention group do not indicate any potential harm. This will include two visits by a trainer to instruct the participant in an appropriate exercise programme.
Intervention typeBehavioural
Primary outcome measureFeasibility in terms of adherence, safety and process. Measures will be taken at baseline and 13 weeks. A follow-up telephone call will be made at 26 weeks to conduct the IPAQ and EQ-5D.
Secondary outcome measuresAssess benefit including physical fitness, cognitive ability and motor function. Measures will be taken at baseline and 13 weeks. A follow-up telephone call will be made at 26 weeks to conduct the IPAQ and EQ-5D.
Overall study start date01/02/2014
Completion date31/08/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned sample size: 42. UK sample size: 26. International sample size: 16
Key inclusion criteria1. Diagnosis of manifest HD, confirmed by genetic testing
2. Male and female above the age of 18
3. Stable medication regime for four weeks prior to initiation of trial, and anticipated to be able to maintain a stable regime for the course of trial
4. Enrolled in European Huntington Disease Network (EHDN) Registry/ENROLL-HD study
Key exclusion criteria1. Any physical or psychiatric condition that would prohibit the participant from completing the intervention or the full battery of assessments
2. Inability to independently use the cycle ergometer
3. Unable to understand or communicate in spoken English (UK sites only)
4. Currently involved in any intervention trial or within four weeks of completing an intervention trial
5. Current, regular participation in a structured exercise programme five times per week or more
Date of first enrolment01/02/2014
Date of final enrolment31/08/2014

Locations

Countries of recruitment

  • Germany
  • Netherlands
  • United Kingdom
  • Wales

Study participating centre

Cardiff University
Cardiff
CF14 4XN
United Kingdom

Sponsor information

Cardiff University (UK)
University/education

Research, Innovation and Enterprise Services
7th Floor McKenzie House
30-36 Newport Road
Cardiff
CF24 0DE
Wales
United Kingdom

Website http://www.cardiff.ac.uk/
ROR logo "ROR" https://ror.org/03kk7td41

Funders

Funder type

Charity

Jacques and Gloria Gossweiller Foundation (Switzerland)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/10/2016 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

19/07/2016: Publication reference added.